Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Research Area, Technology (NGS, PCR, Mass Spectrometry), Disease (Cancer, Infectious), Application (Diagnostics, Clinical Research) - Global Forecast to 2029
The global biomarkers market in terms of revenue was estimated to be worth $57.7 billion in 2024 and is poised to reach $93.8 billion by 2029, growing at a CAGR of 10.2% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The market's growth is mainly driven by the high adoption of advanced technologies like NGS and the increasing number of research studies on the discovery and development of novel cancer biomarkers.
Biomarkers Market - Global Forecast to 2029
To know about the assumptions considered for the study, Request for Free Sample Report
Attractive Opportunities in the Biomarkers Market
Global Biomarkers Market Dynamics
DRIVER: Increase in global prevalence of cancer
Biomarkers play a crucial role in indicating various health or disease characteristics. Cancer, being a complex disease, undergoes a multistage carcinogenesis process involving numerous molecular pathway events, posing challenges in diagnosis, prognosis, and therapy. Given this complexity, relying on a single marker is insufficient. Furthermore, each cancer type exhibits unique molecular profiles. The discovery of novel biomarkers presents opportunities to develop therapeutic strategies aimed at addressing dysregulation in cancer. Consequently, the rising incidence of cancer will fuel biomarker research and subsequently contribute to the expansion of the biomarkers market.
RESTRAINT: Disease complexity and heterogeneity
The complexity and heterogeneity inherent in diseases pose challenges to the advancement of biomarkers. With diverse molecular pathways and clinical presentations among individuals, identifying universal biomarkers becomes a daunting task. Disease heterogeneity complicates this further, as different patients exhibit distinct molecular signatures, making it challenging to find common biomarkers applicable across populations. Additionally, disease progression is dynamic, requiring biomarkers to adapt to changing conditions over time. These complexities hinder translating biomarker research into clinical practice, where biomarkers must accurately reflect the diverse disease manifestations for effective diagnosis, prognosis, and treatment monitoring. Thus, addressing the intricacies of disease complexity and heterogeneity is crucial for the successful development and implementation of biomarkers in healthcare settings.
OPPORTUNITY: Shift towards personalized medicine and precision oncology
Biomarkers play an essential role in the selection of targeted therapies that specifically address the molecular characteristics of a patient's tumor. For example, specific genetic mutations or alterations in cancer cells can make them susceptible to inhibition by targeted drugs. Biomarker testing helps identify these molecular aberrations, enabling oncologists to choose the most effective treatment for each patient.
Biomarker-driven approaches help identify patients who are most likely to benefit from a particular treatment, reducing the risk of exposing individuals to therapies that are unlikely to be effective or may cause significant side effects. This personalized approach enhances patient safety and quality of life during cancer treatment.
CHALLENGE: Challenges associated with integration of complex data sets
The integration of complex data sets in biomarker research poses significant challenges to market growth. Biomarker data, sourced from diverse platforms such as traditional blood tests, next-generation sequencing (NGS), and fluorescence in situ hybridization (FISH) testing, is voluminous, diverse, and rapidly evolving. The absence of universal standards for reporting, particularly in NGS-derived data, complicates data interpretation and aggregation across different organizations and testing methodologies. Moreover, disparities in biomarker testing across racial, ethnic, and economic groups further hinder data accessibility and completeness. Limited coverage by health plans and disparities in clinical trial enrollment exacerbate these challenges, leading to inaccessible, incomplete, or poorly representative biomarker datasets.
Global Biomarkers Industry Ecosystem Analysis
The biomarkers market ecosystem comprises raw material suppliers, product & service providers, regulatory authorities, and end users, such as academic & research institutes, hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies, and other end users
The immunoassays segment held a dominant share in the technology segment in the biomarkers industry.
Based on the technology, the biomarkers market has been segmented into immunoassays (western blot, ELISA, and protein microarray), NGS, PCR, mass spectrometry, chromatography, and other technologies. In 2023, immunoassays accounted for the largest share of the biomarkers market. This is attributed to the growing need for immunoassays during the drug development process, as drug development puts much pressure on costs and sample usage.
The clinical diagnostic segment is expected to register the fastest growth of biomarkers industry during the forecast period.
Based on the application, the biomarkers market has been segmented into clinical diagnostics, drug discovery & development, personalized medicine, clinical research, and other applications. In 2023, the clinical diagnostic segment accounted for the largest market share and is expected to achieve the highest CAGR during the projected period. The key drivers of clinical diagnostics in the biomarkers market include the use of biomarkers for disease detection, diagnosis, prognosis, and monitoring of therapeutic responses in clinical settings.
North America accounted for the largest share of the biomarkers industry in 2023
Geographically, the biomarkers market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America held the dominant share, followed by Europe. North America has been a leader in supporting research for the development of novel drugs. Thus, the development of novel therapies and a growing number of clinical trials in the region are contributing to the growth of the North American biomarkers market.
To know about the assumptions considered for the study, download the pdf brochure
Key players in the global biomarkers market includeF. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), BIOMÉRIEUX (France), Agilent Technologies, Inc. (US), JSR Corporation (Japan), Quanterix (US), MESO SCALE DIAGNOSTICS, LLC. (US), EKF Diagnostics (UK), Celerion (US), Standard BioTools (US), Sebia (France), BioAgilytix Labs (US), StressMarq Biosciences Inc. (Canada), NorthEast BioAnalytical Laboratories LLC (US), Signosis, Inc. (US), Serimmune (US), TheraIndx Lifesciences Pvt. Ltd. (India), Synexa Life Sciences BV (Netherlands), Diatech Pharmacogenetics (Italy), Singulex, Inc. (US), R-Biopharm AG (Germany), and Proteome Sciences (UK).
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market size available for years |
2022–2029 |
|
Base year considered |
2023 |
|
Forecast period |
2024–2029 |
|
Forecast units |
Value (USD) |
|
Segments covered |
Product & Service, Type, Research Area, Technology, Disease Indication, Application, and End User |
|
Geographies covered |
North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
|
Companies covered. |
F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), BIOMÉRIEUX (France), Agilent Technologies, Inc. (US), JSR Corporation (Japan), Quanterix (US), MESO SCALE DIAGNOSTICS, LLC. (US), EKF Diagnostics (UK), Celerion (US), Standard BioTools (US), Sebia (France), BioAgilytix Labs (US), StressMarq Biosciences Inc. (Canada), NorthEast BioAnalytical Laboratories LLC (US), Signosis, Inc. (US), Serimmune (US), TheraIndx Lifesciences Pvt. Ltd. (India), Synexa Life Sciences BV (Netherlands), Diatech Pharmacogenetics (Italy), Singulex, Inc. (US), R-Biopharm AG (Germany), and Proteome Sciences (UK). |
This report categorizes the biomarkers market into the following segments
Biomarkers market, by Product & Service
-
Consumables
- Assays Kits
- Reagents & Chemicals
- Columns & Filters
- Services
- Software
Biomarkers Market, by Type
- Safety Biomarkers
-
Efficacy Biomarkers
- Predictive Biomarkers
- Surrogate Biomarkers
- Pharmacodynamic Biomarkers
- Prognostic Biomarkers
- Validation Biomarkers
Biomarkers Market, by Research Area
- Genomics
- Proteomics
- Metabolomics
- Other research areas
Biomarkers Market, by Technology
-
Immunoassays
- ELISA
- Western Blot
- Protein Microarray
- PCR
- Mass Spectrometry
- NGS
- Chromatography
- Other technologies
Biomarkers Market, by Disease Indication
- Cancer
- Infectious Disease
- Immunological Disorder
- Cardiovascular Disorder
- Other Disease Indications
Biomarkers Market, by Application
- Clinical Diagnostics
- Drug Discovery & Development
- Personalized Medicine
- Clinical Research
- Other applications
Biomarkers market, by End User
- Pharmaceutical & Biotechnology Companies
- Hospitals & Diagnostic Laboratories
- Academic & Research Institutes
- Other end users
Biomarkers market, by Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
-
Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific (RoAPAC)
-
Latin America
- Brazil
- Mexico
- Rest of Latin America (RoLATAM)
-
Middle East & Africa
-
Middle East
-
GCC Countries
- Saudi Arabia (KSA)
- United Arab Emirates (UAE)
- Rest of GCC Countries
- Rest of Middle East (RoME)
-
GCC Countries
- Africa
-
Middle East
Recent Developments of Biomarkers Industry:
- In January 2024, Quibim and Merck KGaA partnered to develop diagnostic tools to develop the next generation of precision medicine technology targeting a wide range of cancers
- In October 2023, Quanterix Corporation, a company specializing in ultrasensitive biomarker detection, has announced a new agreement with Johnson & Johnson's Janssen Sciences Ireland UC to advance blood-based Alzheimer's disease detection. The agreement grants Quanterix non-exclusive rights to J&J's p-Tau 217 antibodies and assay designs, enabling the development of a potential Laboratory Developed Test (LDT) for Alzheimer's Disease (AD) diagnosis and clinical research
- In February 2023, F. Hoffmann-La Roche Ltd launched two new antibodies to understand a patient's brain tumor mutation status in the IDH1 and ATRX genes that help in more informed clinical decisions and may improve patient outcomes
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global biomarkers market?
The global biomarkers market boasts a total revenue value of $93.8 billion by 2029.
What is the estimated growth rate (CAGR) of the global biomarkers market?
The global biomarkers market has an estimated compound annual growth rate (CAGR) of 10.2% and a revenue size in the region of $57.7 billion in 2024. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information to analyze the global biomarkers market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the biomarkers market. The secondary sources used for this study include American Society of Clinical Oncology (ASCO), Canadian Alliance for Healthy Hearts and Minds (CAHHM), Canadian Institute for Health Information (CIHI), Central Drugs Standard Control Organization (CDSCO), Center for Disease Evaluation and Research (CDER), Centers for Disease Control and Prevention (CDC), Chinese Medical Journal, Clinicaltrials.gov.in, European Medicines Agency (EMA), Food and Drug Administration (FDA), GLOBOCAN, International Agency for Research on Cancer (IARC), National Cancer Institute (NCI), National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), National Comprehensive Cancer Network (NCCN), Organization for Economic Co-operation and Development (OECD), Population Health Research Institute (PHRI), PubMed, World Bank, World Health Organization (WHO), Corporate and Regulatory Filings, Annual Reports, Sec Filings, Investor Presentations, and Financial Statements; Business Magazines & Research Journals; Press Releases, MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global biomarkers market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & and biotechnology companies, hospitals & diagnostic laboratories, academic & research institutes, and other end users) and supply side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, across six major regions—North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa. Approximately 70% of primary interviews were conducted with supply-side representatives, while demand-side participants accounted for the remaining share. This preliminary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the biomarkers market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Bottom-up Approach
- The key players in the industry and market have been identified through extensive secondary research.
- The revenues generated from the biomarkers market business of leading players have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
To know about the assumptions considered for the study, Request for Free Sample Report
Top-down Approach
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.
Data Triangulation
To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
A biomarker is a defining characteristic that is a measurable indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Biomarkers are objective indications of medical states observed from outside the patient, which can be measured accurately and reproducibly. They can be used as diagnostic tools for identifying patients with abnormal conditions, as tools for staging the extent of a disease, as indicators of disease prognosis, or for predicting and monitoring a response to an intervention.
The scope of this report includes products, software, and services, including consumables such as assay kits, reagents and chemicals, and columns and filters supporting the biomarker detection and analysis processes, as well as software and services related to biomarker detection and analysis.
Stakeholders
- Academic & Research Institutes
- Biomarkers Assays and Reagents Manufacturers, Vendors, and Distributors
- Contract Research Organizations (CROs)
- Biomarkers Service & Software Providers
- Diagnostics Companies
- Market Research and Consulting Firms
- Pharmaceutical and Biotechnology Companies
- Regulatory Agencies
- Venture Capitalists
- Forensics Labs
- Government organizations
- Private research firms
- Contract development and manufacturing organizations (CDMOs)
- Hospitals and Diagnostic Laboratories
Report Objectives
- To define, describe, and forecast the global biomarkers market based on product & service, type, research area, technology, disease indication, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global biomarkers market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations in the biomarkers market
- To benchmark players in the biomarkers market using the “Company Evaluation Matrix” framework, which analyzes market players based on various parameters, including product portfolio, geographic reach, and market share
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe biomarkers market, by country
- Further breakdown of the Rest of Asia Pacific biomarkers market, by country
- Further breakdown of the Rest of Latin America biomarkers market, by country
- Further breakdown of the Rest of Middle East biomarkers market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Further breakdown of the other technologies and other therapeutic area into subsegments
- Cross-segment analysis
Generating Response ...
Growth opportunities and latent adjacency in Biomarkers Market
Looking forward to gain more insights on the global Biomarkers Market
What are the growth opportunities in Biomarkers Market?
Can you enlighten us on the end users in Biomarkers Market?